Market Place
Sourcing Support
MediciNova`s MN-166 Abstract Accepted For Poster Presentation
09 Sep 2024 //
GLOBENEWSWIRE
MediciNova`s MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting
03 Sep 2024 //
GLOBENEWSWIRE
MediciNova Receives Patent Notice for MN-166 in Post-COVID Condition
29 Aug 2024 //
GLOBENEWSWIRE
MediciNova`s MN-166 Glioblastoma Data At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
MediciNova Allowed Patent Covers MN-166 Eye Cancer Metastasis Prevention
20 May 2024 //
GLOBENEWSWIRE
MediciNova to receive US patent ibudilast to treat chlorine-induced acute RDS
15 May 2024 //
PHARMABIZ
MediciNova Allowed Patent For MN-166 In Chlorine-Induced ARDS
14 May 2024 //
GLOBENEWSWIRE
MediciNova New MN-166 Patent For Extended-Release Formulation
07 May 2024 //
GLOBENEWSWIRE
MediciNova Announces Abstract of Trial ibudilast at the 2024 ASCO
02 Apr 2024 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166
26 Mar 2024 //
GLOBENEWSWIRE
MediciNova Announces New Data and Results of MN-166
12 Mar 2024 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166
17 Jan 2024 //
GLOBENEWSWIRE
MediciNova Announces Abstract Regarding MN-166 in Lung Injury
21 Dec 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Decision to Grant for Patent Covering MN-166
06 Dec 2023 //
GLOBENEWSWIRE
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166
19 Nov 2023 //
GLOBENEWSWIRE
MediciNova Receives Allowance for Patent Covering the Combination of MN-166
10 Oct 2023 //
GLOBENEWSWIRE
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166
27 Sep 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Intention to Grant for a Patent Covering MN-166
16 Aug 2023 //
GLOBENEWSWIRE
MediciNova Announces Presentation of Results from the Ph 2b Trial of MN-166
29 Jun 2023 //
GLOBENEWSWIRE
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-166
14 May 2023 //
GLOBENEWSWIRE
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166
09 Mar 2023 //
GLOBENEWSWIRE
MediciNova Announces Data Regarding MN-166 in Glioblastoma Tumor Tissue Analysis
20 Feb 2023 //
GLOBENEWSWIRE
MediciNova Announces Completion of Enrollment in PII Trial Evaluating MN-166
12 Jan 2023 //
GLOBENEWSWIRE
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of MN-166
05 Jan 2023 //
GLOBENEWSWIRE
MediciNova Announces +Ve Results from Secondary Analysis of Ph2 Trial of MN-166
05 Dec 2022 //
GLOBENEWSWIRE
MediciNova Receives Issue Notification for a New Patent Covering MN-166
14 Sep 2022 //
GLOBENEWSWIRE
MediciNova enters deal to take part in long Covid treatment trial
17 Aug 2022 //
CLINICALTRIALSARENA
MediciNova to Participate in Grant-Funded Clinical Trial to Evaluate MN-166
16 Aug 2022 //
GLOBENEWSWIRE
MediciNova Announces Extension of BARDA Contract to Develop MN-166
29 Jun 2022 //
GLOBENEWSWIRE
MediciNova Announces Positive Top-Line Results from PII Trial of MN-166
08 Jun 2022 //
GLOBENEWSWIRE
MediciNova Completes Enrollment in PII Trial of MN-166 in COVID-19 Patients
12 Apr 2022 //
GLOBENEWSWIRE
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166
07 Apr 2022 //
GLOBENEWSWIRE
MediciNova Announces MN-166 Identified as Potential Beneficial Pharmacotherapy
28 Feb 2022 //
GLOBENEWSWIRE
MediciNova Says MN-166 as Promising Pharmacotherapy for Alcohol Use Disorder
22 Feb 2022 //
GLOBENEWSWIRE
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-166
27 Jan 2022 //
GLOBENEWSWIRE
MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd
10 Dec 2021 //
GLOBENEWSWIRE
MediciNova Announces New Data regarding MN-166 (ibudilast)
22 Nov 2021 //
GLOBENEWSWIRE
MediciNova Announces New Data regarding MN-166 (ibudilast)
10 Nov 2021 //
GLOBENEWSWIRE
MediciNova Announces New Data regarding MN-166 in Glioblastoma
03 Nov 2021 //
GLOBENEWSWIRE
MediciNova’s MN-166 to treat ophthalmic disease receives US patent
08 Jul 2021 //
PHARMABIZ
MediciNova Receives Notice of Allowance for New Patent Covering MN-166
06 Jul 2021 //
GLOBENEWSWIRE
MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166
28 Jun 2021 //
GLOBENEWSWIRE
MediciNova Announces Positive Results from Phase 2 Trial of MN-166
21 Jun 2021 //
GLOBENEWSWIRE
MediciNova to receive European patent covering combo of for budilast
06 May 2021 //
PHARMABIZ
MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)
19 Jan 2021 //
GLOBENEWSWIRE
MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)
29 Dec 2020 //
GLOBENEWSWIRE
MediciNova, in Collaboration with the University of Sydney MN-166
22 Oct 2020 //
GLOBENEWSWIRE
MediciNova slumps 23% on ibudilast data in chemo-induced nerve damage
24 Sep 2020 //
SEEKING ALPHA
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast)
25 Jun 2020 //
GLOBENEWSWIRE
Yale University launches trial to asses ibudilast for Covid-19
24 Apr 2020 //
CLINICALTRIALSARENA
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166
21 Apr 2020 //
GLOBENEWSWIRE
MediciNova to study ibudilast for Covid-19-related ARDS
08 Apr 2020 //
CLINICALTRIALSARENA
MediciNova Receives Notice of Allowance for New Patent Covering MN-166
28 Oct 2019 //
BIOSPACE
MediciNova Announces Ph 3 Trial Plan for MN-166 (ibudilast) in Progressive MS
12 Jul 2019 //
GLOBE NEWSWIRE
MediciNova Announces Initiation of Clinical Trial of MN-166 (ibudilast)
09 Jan 2019 //
GLOBENEWSWIRE
NIAAA Awards Research Grant to UCLA for Ph 2b Trial of Ibudilast
20 Aug 2018 //
DIRECTORS TALK
MediciNova’s Drug Flunks Phase II Trial
29 Mar 2018 //
BIOSPACE
Drug Shows Promise for Treating Alcoholism
02 Feb 2017 //
DDDMAG
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166
11 Oct 2016 //
GLOBENEWSWIRE
MediciNova`s Ibudilast And The Phase IIb Trial Offer Steady Outlook
18 Jan 2016 //
SEEKING ALPHA
